Re-challenging pralsetinib following recovery from pneumocystis jirovecii pneumonia in a lung cancer patient: a Case Report [PDF]
Frontiers in PharmacologyBackgroundPneumocystis jirovecii pneumonia (PJP), an opportunistic infection, is commonly observed in immunocompromised individuals, particularly those with cancer, and is known for its significant morbidity and mortality rates.
Longbin Pang, Surui Liu
exaly +4 more sources
Pathologic complete response to pralsetinib in stage IV RET-positive non-small cell lung cancer: A case report [PDF]
Respiratory Medicine Case ReportsNeoadjuvant therapy with tyrosine kinase inhibitors has been proposed as a feasible approach for downstaging potential resectable non-small cell lung cancer (NSCLC).
Mingxiang Ye
exaly +4 more sources
Understanding Postmarketing Requirements and Commitments for CYP3A-Mediated Drug-Drug Interactions: An Analysis of FDA-Approved Drugs From 2015 to 2024. [PDF]
Clin Transl SciABSTRACT Addressing knowledge gaps at drug approval through drug–drug interaction (DDI)‐related postmarketing requirements (PMRs) and commitments (PMCs) is essential for safe and effective use. This analysis reviewed CYP3A‐related PMRs and PMCs, the most evaluated enzyme in postmarketing studies, to characterize their scope.
Yu J +4 more
europepmc +2 more sources
JTO Clinical and Research Reports, 2023 Selpercatinib and pralsetinib are RET inhibitors with substantial activity in advanced RET-rearranged NSCLC. We present a case of pralsetinib-related pneumonitis and leptomeningeal and brain metastases progression during treatment suspension for ...
Sanjay Popat
exaly +3 more sources
Radioiodine-Refractory Differentiated Thyroid Cancer: Definition, Molecular Mechanisms, and Advances in Precision Therapy. [PDF]
Cancer InnovRadioiodine‐refractory differentiated thyroid cancer (RAIR‐DTC) management now spans selective kinase inhibitors, MAPK‐pathway redifferentiation, VEGFR multikinase TKIs, and biomarker‐driven immunotherapy. We propose a three‐axis decision framework integrating molecular driver, evidence level, and patient dimension to guide individualized treatment ...
Li Y, He Z.
europepmc +2 more sources
GDNF-RET signaling drives pulmonary neuroendocrine cell hyperplasia and allergic airway inflammation. [PDF]
FEBS LettA neuroimmune interaction centered on the PNEC‐ILC2 axis in an asthma model. PNEC‐derived CGRP activates nearby ILC2s, which then release cytokines, including IL‐5 and IL‐13. These cytokines promote eosinophil and macrophage infiltration. Subsequently, GDNF produced by these cells induces PNEC hyperplasia via the GDNF receptors, RET and GFRα1 ...
Kawano T, Ike E, Okada S, Takahashi T.
europepmc +2 more sources
Real-world FAERS safety analysis of Pralsetinib [PDF]
Scientific ReportsThe FDA has approved pralsetinib as a chemotherapeutic drug for the treatment of individuals with cancers such as medullary thyroid cancer (MTC), papillary thyroid cancer (PTC), and non-small cell lung cancer (NSCLC).
Dongdong Zhang +6 more
doaj +2 more sources
Efficacy and safety of pralsetinib in multiple endocrine neoplasia type 2-associated pheochromocytoma: a case report [PDF]
Therapeutic Advances in Endocrinology and MetabolismA 34-year-old male developed bilateral recurrent pheochromocytomas 10 years after laparoscopic adrenal-sparing surgery for pheochromocytomas. Based on his clinical manifestations and germline REarranged during Transfection (RET) variant, the patient was ...
Shiwei Chen +7 more
doaj +2 more sources
The RET inhibitor pralsetinib suppresses TMZ-resistant glioma growth by regulating spermine production [PDF]
Frontiers in PharmacologyObjectiveGlioma is the most common malignant tumor of the central nervous system and is characterized by altered cellular metabolism. Although temozolomide (TMZ)-based adjuvant treatment has improved overall patient survival, clinical outcomes remain ...
Lingyun Ma +11 more
doaj +2 more sources
Dual targeting of RET and SRC synergizes in RET fusion-positive cancer cells. [PDF]
Mol OncolDespite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Son J +13 more
europepmc +2 more sources